Page last updated: 2024-12-07
benzylidene glucose
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 100089 |
CHEMBL ID | 1986984 |
SCHEMBL ID | 12032224 |
MeSH ID | M0061946 |
Synonyms (26)
Synonym |
---|
NCI60_002922 |
nsc-333861 |
nsc333861 |
mls003170843 , |
.alpha.-d-glucopyranose,6-o-(phenylmethylene)- |
25152-90-3 |
4,6-o-benzylidene-d-galactose |
nsc243486 |
nsc-243486 |
OPREA1_571051 |
benzylidene glucose |
2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxine-6,7,8-triol |
FT-0654761 |
FT-0662806 |
smr001874760 |
.alpha.-d-glucopyranose, 4,6-o-(phenylmethylene)- |
alpha-d-glucopyranose, 4,6-o-(phenylmethylene)- |
p-1013 |
nsc 333861 |
CHEMBL1986984 |
SCHEMBL12032224 |
AKOS030212689 |
4-o,6-o-benzylidene-alpha-d-glucopyranose |
SY224230 |
mfcd00057743 |
A919199 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" It was found that BG rapidly disappeared with a half-life (t1/2) on the order of 10 min." | ( In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats. Børretzen, B; Dornish, JM; Larsen, RO; Pettersen, EO; Schwarze, PE, 1990) | 0.28 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In this study we compared the bioavailability of BG and P-1013, since both intraperitoneal and, especially, oral administration of the drugs would be a great advantage." | ( The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats. Dornish, JM; Dunsaed, CB; Pettersen, EO, 1995) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (27.27) | 18.7374 |
1990's | 6 (54.55) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.78
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.78) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |